Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating diabetic ulcer

A technology for diabetic ulcers and drugs, applied in the field of biomedicine, can solve the problems of Nrf2 agonist-CA application strategy is not safe and simple, and achieve good therapeutic effect, improve wound healing, and safe and convenient use

Active Publication Date: 2017-09-05
THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of this, the purpose of the present invention is to provide a locally applied and safe drug for the treatment of diabetic ulcers, so as to solve the problem that the current Nrf2 agonist-CA application strategy in diabetic ulcers is not safe and simple

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating diabetic ulcer
  • Medicine for treating diabetic ulcer
  • Medicine for treating diabetic ulcer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The present invention will be further described below in conjunction with the accompanying drawings and embodiments.

[0014] The drug for treating diabetic ulcers in this embodiment is a gel composed of solute: cinnamaldehyde and solvent: PEG 400, and the concentration range of cinnamaldehyde in the gel is 1.2-20 μmol / L.

[0015] Taking the preparation of 1 mL of 4 μmol / L cinnamaldehyde gel as an example, the preparation method of the drug for treating diabetic ulcers in this embodiment is introduced, and the specific steps are as follows:

[0016] Step 1: Prepare 1 mL of 20 mmol / L cinnamaldehyde gel

[0017] 1) The number of moles of CA contained in 1mL 20mmol / L cinnamaldehyde gel:

[0018] 2) n=c×v

[0019] no CA =(20mmol / L)×(1mL)=20×10 -6 mol

[0020] 3) m=n×M

[0021] m CA =(20×10 -6 mol)×132.16=2.6432×10 -3 g

[0022] 4) v=m / ρ

[0023] v CA =(2.6432×10 -3 g)÷(1.05g / mL)=2.517ul

[0024] Add 2.517ul of CA into 1ml of PEG400, and shake at high speed to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine for treating diabetic ulcer. The medicine is gel consisting of solute, cinnamyl aldehyde, a solvent and PEG 400 (Polyethylenglycol 400), wherein the concentration of the cinnamyl aldehyde in the gel is 1.2-20mu mol / L. The medicine for treating diabetic ulcer is at a gel state, is smeared at wounds when being used, is capable of remarkably improving diabetic wound healing, and is good in treatment effect and safe and convenient to use.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a medicine for external use for treating ulcers. Background technique [0002] Chronic skin ulcers that do not heal for a long time, eventually leading to amputation, are the main cause of disability caused by diabetes, and urgent research is needed to solve them. As the main component of organic extracts in cinnamon, CA is not only an α,β-unsaturated aldehyde compound approved by the FDA for food (21CFR§182.60), but also approved by the American "Spice and Extract Manufacturers Association (FEMA )" gave the "generally recognized as safe" instructions for use (NO.2286). In addition, a large number of human studies have recorded the systemic pharmacokinetics and safety characteristics of its application, suggesting that it has broad potential clinical application prospects. [0003] At present, clinical studies have confirmed that the skin oxidative stress damage in diabetic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/06A61K31/11A61K47/10A61P17/02A61P3/10
CPCA61K9/0014A61K9/06A61K31/11A61K47/10
Inventor 隆敏郑宏庭蔡雷琴
Owner THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com